Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?

Gloria TsvetovO AmitaiT ShochatI ShimonA AkirovTalia Diker Cohen

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2019)

Real-life rates of denosumab-induced hypocalcemia are higher than previously reported. Hypocalcemia might develop after each dose of denosumab in ongoing treatment. Adequate calcium and vitamin D supplementation are needed. Serum calcium monitoring is advised in high-risk patients for early detection of severe hypocalcemia.

Keyphrases

bone mineral density
high glucose
end stage renal disease
postmenopausal women
giant cell
diabetic rats
newly diagnosed
drug induced
chronic kidney disease
body composition
endothelial cells
prognostic factors
early onset
combination therapy